ArticleScientific reports2025
3D-printed optogenetic neural probe integrated with microfluidic tube for opsin/drug delivery.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Crosstalk-free optical indicator-actuator combinations for bidirectional optogenetics.npj biomedical innovations · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optogenetics, known for its precision in neural stimulation, is integral to behavioral research, enabling the study of neural circuits involved in decision-making, memory, social interaction, and movement. Traditional methodologies require two separate surgeries: the first to deliver a viral vector containing the opsin gene to the targeted brain region, and the second to implant an opto-probe for light stimulation. This dual-step process increases the risk of tissue damage and misalignment between the injection and implantation sites. In this study, we present a 3D-printed multimodal optogenetic neural probe that combines light delivery and fluid injection into a single device. By integrating a commercially available microfluidic tube with a 3D-printed opto-probe, the device offers rapid and customizable assembly for diverse applications. The probe was implanted in the subthalamic nucleus of mice, enabling viral vector delivery and device implantation in a single procedure. Following viral expression, behavioral experiments demonstrated that optical stimulation increased travel distance and velocity, confirming effective neuronal activation. Immunohistochemistry analysis revealed successful expression of Channelrhodopsin-2 (ChR2(H134R)) through mCherry labeling of neurons, reduced astrocytic (GFAP) and microglial (ED1) activation around the implantation site, and preserved neuronal populations as confirmed by NeuN staining. These results highlight the device's biocompatibility, minimal inflammatory response, and suitability for long-term neural modulation, with potential applications in research and clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.